GlassScriptPhysician profile
George H Moore
NPI 1942344494
$4,923.99
in general payments reported to CMS, 2019-2025
25 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $153 · 2021: $356 · 2022: $691 · 2023: $1,021 · 2024: $1,313 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.04 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,030.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $842.59 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $615.09 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $562.89 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $438.38 | 2019-2025 | Repatha, Repatha, Otezla |
| Daiichi Sankyo INC. | $329.89 | 2019-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $300.87 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.46 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $153.71 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $79.98 | 2024 | Inspire |
| Eisai INC. | $52.99 | 2024-2025 | |
| Masimo Corporation | $40.88 | 2023-2025 | Set and Rainbow Set, Patient Safetynet System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.41 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $32.16 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $26.53 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.96 | 2023 | Amplatzer Amulet |
| Medtronic, INC. | $18.88 | 2022 | |
| Lundbeck LLC | $15.66 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $15.62 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $13.09 | 2023 | Onpattro |
| Pfizer INC. | $12.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 | |
| Allergan, INC. | $12.11 | 2020 | |
| Amarin Pharma, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.